Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies – GlobeNewswire (press release)
GeekWire |
Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
GlobeNewswire (press release) 14, 2017 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) … Fred Hutch licenses new immunotherapy treatment to Mustang Bio, preps pre-clinical trials in Seattle |
